Antibe Provides Scientific Report on Its Recently Completed Phase 2B Study Showing Unequivocal Gastrointestinal Safety of ATB-346

Stock Information for Antibe Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.